$1.00
$7.17
52-Week Range
At a Glance
AI-generatedPepGen Inc.
8-K
PepGen Inc. announced topline results from the 5 mg/kg cohort of its Phase 2 FREEDOM2-DM1 trial, showing PGN-EDODM1 was generally well-tolerated with favorable splicing and vHOT data, supporting the ongoing 10 mg/kg cohort.$121M
Market Cap
—
Revenue
-$147M
Net Income
Employees79
Fundamentals
How The Business Makes Money
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001835597
ISINUS7133171055
CUSIP713317105
Phone781-797-0979
Address245 Main Street, Boston, MA, 02142, US
SEC EDGAR